Oruka Therapeutics (ORKA) Interest Expenses (2010 - 2026)

Oruka Therapeutics' Interest Expenses history runs 17 years deep, the most recent figure standing at $161.0 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 3322.34% year-over-year to $161.0 million in Q1 2026; TTM through Mar 2026 was $161.0 million, a 3322.34% increase from a year earlier, with the FY2025 full-year figure at $70.0 million, up 228.22% from the prior year.
• Interest Expenses grew to $161.0 million in Q1 2026 per ORKA's latest filing, from -$14.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $161.0 million in Q1 2026 and bottomed at -$32.3 million in Q4 2024.
• The 5-year median for Interest Expenses is $423500.0 (2022), against an average of $12.5 million.
• Biggest YoY gain for Interest Expenses was 34122.22% in 2024; the steepest drop was 124330.77% in 2024.
• Year by year, Interest Expenses stood at $65000.0 in 2022, then sank by 60.0% to $26000.0 in 2023, then plunged by 124330.77% to -$32.3 million in 2024, then jumped by 54.8% to -$14.6 million in 2025, then surged by 1202.65% to $161.0 million in 2026.
• Per Business Quant, the three latest ORKA Interest Expenses figures stand at $161.0 million (Q1 2026), -$14.6 million (Q4 2025), and $30.9 million (Q3 2025).